Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.

The US giants which supply vital new medicines to UK patients face disruption from Donald Trump’s trade barriers, experts ...

After decades of mostly unsuccessful R&D, Amgen has claimed the first ever ... The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c ...

Amgen (AMGN) ended the recent trading session at $314.38, demonstrating a -0.53% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1.77%.

In the latest trading session, Amgen (AMGN) closed at $318.65, marking a +0.47% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.07%. Elsewhere, the Dow lost 0.62% ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea. A U.S.

Now two KRAS inhibitors, Amgen’s sotorasib (Lumakras) and BMS/Mirati’s adagrasib (Krazati), are approved — and many more are in the clinic. But while clinicians had high hopes that these ...

In January and February of this year, the US Food and Drug Administration granted approvals for Adcetris (brentuximab vedotin), Lumakras (sotorasib), Grafapex (treosulfan), Enhertu (fam ...

Am­gen has shared ad­di­tion­al Phase 3 da­ta for its rare dis­ease drug Up­liz­na in myas­the­nia gravis, bol­ster­ing the com­pa­ny’s case for la­bel ex­pan­sion be­fore a … ...

Credit: shutterstock / CGN089. Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of generalised myasthenia gravis (gMG) patients after 52 weeks in a Phase III trial. Results ...